American Academy of Family Physicians Researchers explored the incidence of erythrocytosis in the first 20 months of testosterone therapy among people receiving gender-affirming hormone therapy (GAHT). Specifically, they conducted a descriptive fixed cohort study of hematocrit and hemoglobin data from the charts of 282 people taking testosterone for GAHT. During the first 20 months of testosterone therapy, the cumulative incidence of hematocrit levels over 50.4% was 12.6%; hematocrit levels over 52% was 1.
https://www.miragenews.com/severe-erythrocytosis-rare-in-testosterone-1091505/#miragenews
Sinun täytyy kirjautua sisään ennen kuin voit kommentoida.